Bile duct cancer

Disease Description (Causes and Symptoms)

• Definition and pathophysiology: Cholangiocarcinoma is an adenocarcinoma arising from the epithelium (cholangiocytes) of the bile ducts (intrahepatic, perihilar, or distal), and is classified according to anatomical location as intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, or distal cholangiocarcinoma. When the tumor obstructs the bile duct, bile stasis (cholestasis) occurs, causing increased bilirubin and bile acids and related symptoms.
• Major causes and risk factors: Chronic cholangitis (e.g., primary sclerosing cholangitis), bile duct stones (intrahepatic stones), clonorchiasis (liver fluke infection), congenital bile duct cysts (choledochal cysts), inflammatory diseases such as ulcerative colitis, and chronic bile duct irritation or scarring. However, the exact cause is not clear.
• Major symptoms:
  • Jaundice (yellowing of the skin and sclera)
  • Gray stools (pale stools), dark urine
  • Pruritus (itching)
  • Weight loss, loss of appetite, fatigue
  • Right upper quadrant or upper abdominal pain (nonspecific)
  • If bile duct obstruction becomes infected, fever (cholangitis) and a risk of sepsis

Treatment Methods (Standard Treatment, Medications, Procedures, Surgery, Lifestyle Management, and Precautions)

• Curative treatment
  • Surgical resection (when complete resection is possible): The procedure varies depending on the tumor location
    • Intrahepatic cholangiocarcinoma: Hepatectomy (or partial hepatectomy)
    • Perihilar cholangiocarcinoma (Klatskin tumor): Liver lobe resection (right or left hepatectomy) with bile duct resection and reconstruction
    • Distal cholangiocarcinoma: Pancreaticoduodenectomy (Whipple procedure)
  • Selective liver transplantation: May be considered in some patients with perihilar cholangiocarcinoma after strict selection criteria and neoadjuvant therapy (radiation and chemotherapy) (protocols vary by center)
• Adjuvant and systemic treatment
  • Postoperative adjuvant therapy: capecitabine (there is relatively supportive evidence for its use as adjuvant therapy)
  • Systemic chemotherapy (for refractory, metastatic, or unresectable disease):
    • Standard first-line treatment: gemcitabine + cisplatin
    • Combination of immunotherapy with first-line treatment (e.g., durvalumab), reflecting a small number of clinical trials and guideline updates (confirm application by center)
  • Targeted therapy (based on molecular markers):
    • Determine whether an FGFR2 fusion is present: pemigatinib, infigratinib, etc., may be considered when an FGFR2 fusion is present
    • ivosidenib for IDH1 mutations
    • Immune checkpoint inhibitors may be considered in cases of MSI-H/dMMR or high TMB
• Local and procedural treatment (palliation and local control for patients who cannot undergo resection)
  • Biliary drainage: ERBD (endoscopic stenting), PTBD (percutaneous transhepatic biliary drainage) — relief of jaundice and protection of liver function
  • Photodynamic therapy (PDT): Used selectively for symptom relief and local control
  • Local ablation/radiation therapy: For symptom relief or control of residual lesions
  • Transarterial chemoembolization (TACE) or Y-90 radioembolization with radioactive microspheres for intrahepatic lesions (depending on the center)
• Management of symptoms and complications
  • Jaundice/itching: Bile acid sequestrants (cholestyramine), rifaxin (not rifaximin), antihistamines, low-dose opioid antagonists, or SSRIs, etc. (The antipruritic medication is selected according to the symptoms)
  • Cholangitis: Antibiotic treatment (in severe cases, hospitalization and drainage are performed together)
  • Nutritional management: Prevention of weight loss and malnutrition (referral to a dietitian)
• Precautions
  • Because some anticancer drugs have dose limitations or are contraindicated in the setting of high bilirubin, jaundice should first be relieved through biliary drainage
  • Stents can become blocked, so regular checks and replacement are necessary
  • Prevention of clonorchiasis and other conditions: Do not eat raw freshwater fish
  • Risks such as infection, bleeding, and liver failure exist before and after surgery

Outpatient Visit Checkpoints (Preparation, Items to Confirm, and Example Questions)

• Items to bring (helpful for determining care and treatment)
  • List of current medications (including prescriptions, OTC medications, and supplements) and allergy history
  • Original copies or reports of previous test results: CT/MRI (especially MRCP) images, ultrasound, PET, ERCP/PTC records, and biopsy results (pathology reports)
  • Recent blood test results (bilirubin, AST/ALT, ALP, GGT, blood count, renal function) and tumor markers (CA19-9, etc.)
  • Symptom records: When jaundice began, weight changes (kg), changes in urine and stool color, and whether fever or pain is present
  • Recent procedure information: Whether a stent was inserted and its type, whether a PTBD tube is in place, and its management status
• Examples of questions to organize in advance for the doctor during the outpatient visit
  • Regarding symptoms: How much weight has recently been lost, and the nature and frequency of the pain
  • Regarding treatment: Previous procedure records (stents and drainage) and whether complications occurred
  • Regarding testing: Whether a previous pathology report (biopsy of the lesion in question) is available
• Other items to confirm
  • Whether anticoagulants are being taken (important before procedures or surgery)
  • History of liver disease (such as cirrhosis) and general medical condition (exercise capacity, respiratory and cardiovascular disease)

Examples of General Questions to Ask the Doctor

• "Is my lesion in a condition that can be cured with surgery? If surgery is recommended, what type of surgery is needed?"
• "Are there any recommended chemotherapy or targeted therapies? What effects and side effects can be expected?"
• "What should I be careful about in daily life to manage jaundice, itching, and pain?"

Examples of Disease-Specific Questions

• "How was the tumor location (intrahepatic/perihilar/distal) and stage (T/N/M or whether it has recurred) determined? Is my lesion currently resectable?"
• "Was molecular genetic testing of the tumor performed (FGFR2, IDH1, MSI, etc.)? Are there targeted therapies available based on the results?"